immunosurgery PGCs

1 **TITLE**

2

3 **Effective Cell Immunoablation in Undisrupted Developing Avian Embryos**

4 Maríacruz López-Díaz^{a‡}, Julia Buján-Varela^b and Carlos Cadórniga-Valiño^a

5

6

^aInstituto Nacional de Investigación y Tecnología Agraria y Alimentaria (INIA). 28040 Madrid - Spain
[‡]Author for correspondence: (lopez.maria@inia.es)

^b Departamento de Especialidades Médicas. Universidad de Alcalá de Henares. 28801 Madrid – Spain, mjulia.bujan uah.es.

immunosurgery PGCs

7 SUMMARY STATEMENT

8 **An immunosurgery procedure is described that yields an almost complete ablation of**
9 **primordial germ cells in early developing chick embryos, thus increasing the expected**
10 **rates of chimerism when foreign PGCs are grafted onto these embryos**

immunosurgery PGCs

11

12 **ABSTRACT**

13 In birds the construction of germline chimeras by grafting exogenous primordial germ cells
 14 (PGCs) during embryonic development is feasible since they migrate to the gonads through
 15 the blood. Up to date, the efficiencies are highly variable, in part dependent on the destruction
 16 of endogenous PGCs in the recipient embryo. We show an almost complete ablation of the
 17 endogenous PGCs in stage X embryos using a baby rabbit serum (BRS), with previous
 18 cellular signaling by specific antibodies (SSEA1). The application of the treatments, either on
 19 epiblast or subgerminally, produced the reduction of the PGCs in the embryos in a dose
 20 dependent manner. No malformations or damages were detected in the treated embryos.
 21 However, subgerminal injection of this cocktail produced a massive cellular destruction in all
 22 embryos. Therefore, sequential application is a selective and effective method to produce
 23 receptor embryos. Nevertheless, it can also be highly destructive if the mixture is applied
 24 locally, this could be useful in the treatment of malignancies.

25

26 **Keywords:** PGCs, immunosurgery, chicken embryos.

27

immunosurgery PGCs

28 INTRODUCTION

29 Very few studies have been done “in vivo” since 1975 when Solter and Knowles coined the
30 term of “immunosurgery”. These authors were able to ablate the trophectoderm cells in mouse
31 embryos by using antibody and complement. In 2007 Chen and Melton by using antibodies
32 against red blood cells and heterologous guinea pig serum as a source of complement,
33 achieved successfully isolation of the inner cell mass in human embryos. Also Gerhart et al.
34 developed an efficient ablation procedure of two epiblast cell types with neuronal and
35 muscular epitopes by using specific antibodies and baby rabbit serum (BRS) in stage X
36 chicken embryos (Gerhart et al 2008, 2010).

37

38 On the other hand, in birds it is needed to develop new assisted reproduction procedures since
39 avian oocytes and embryos are organized as an extremely precise biological structure, the egg.
40 This complex assembly of oocyte/embryo does not stand freezing as is the case of mammalian
41 embryos. Every aspect of the fertilized egg (pH of the different compartments, gas
42 permeability, density relations and floatability, access to the different layers of nutrients, etc)
43 is finely adjusted (Stern 1991, Lopez-Diaz et al. 2016). However, avian embryo has morpho-
44 physiological peculiarities which allow the spread of a genotype or a specific lineage from the
45 precursor cells of sperm and oocytes, the primordial germ cells (PGCs), which can be
46 cryopreserved ex-situ. This assisted reproduction procedure involves the construction of
47 germline chimeras by grafting, during embryonic period, PGCs of the desired lineage on a
48 recipient embryo of a different strain (van de Lavoie 2006).

49

50 The inactivation of the recipient’s germ line has been used as a strategy to improve the degree
51 of germinal chimerism. For decades, the commonly used methods have been irradiation
52 (Maeda et al, 1998, Carsience et al, 1993; Kino et al 1997; Speksnijder and Ivarie, 2000; Lia

immunosurgery PGCs

et al, 2001; Nakamura et al, 2012) or administration of cytotoxic agents (Hemsworth & Jackson 1963; Reynaud 1977; Mozdziak et al 2006; Song et al, 2005; Petite et al 1990; Bresler et al., 1994; Aige Gil V and Simkiss K 1991, Naito et al. 2015). Both are effective, but completely unspecific, equally affecting all populations of embryonic cells, damaging the viability of the recipient embryo. In fact, the results usually achieved have an extremely high variability in the transmission rates of the grafted germline (2.9-100%), whether the endogenous PGCs are inactivated (Naito et al. 2015) or not (van de Lavoie 2006, White et al. 2015), this means that the procedure is not under control.

The origin and migration of avian PGCs have been well characterized (Dubois 1969; Kuwana and Fujimoto, 1984; Muniesa and Dominguez, 1990) since first described by Swift (1914). It has been estimated that the number of PGCs at oviposition (stage X embryo) is 100-120. Such a reduced number of cells and the high potential of developmental plasticity make this developmental stage the best time for the elimination of endogenous PGCs.

On the other hand, the combined cytolytic action of antibodies and complement has been well known for over a century (Wiemann 1994) and has been applied with different therapeutic and experimental purposes. In rabbits previously grafted with cancer cells (Kalfayan & Kidd, 1953) the combination of serum complement with antibodies against Brown-Pearce carcinoma cells achieved effective inhibition of tumor growth. Nowadays, one of the best treatments against cancer is the use of antibodies, with over 20 of different nature approved by various regulatory agencies (Macor & Tedesco 2007). As a consequence, in the last few decades the antibody-complement actions have been deeply investigated. It is known that complement modulates the complement dependent cytotoxicity (CDC) and antibody dependent cytotoxicity (ADCC). However, complement can have opposite effects; it can

immunosurgery PGCs

favor CDC and inhibit ADCC. Our understanding of the mechanisms involved when antibody and complement are acting together is still in its infancy (Rogers et al. 2014).

Like many malignant neoplastic cells, PGCs have a glycocalix rich in trisaccharide Gal β (1-4), Fuc α (1-3)-GlcNAc β 1-R4 which is recognized by antiSSEA1. In fact, antiSSEA1 has been widely used to enrich selectively PGCs from stage X embryos (Etches 1998) and gonocytes from embryos of 5days, stage 27 (Mozdziak 2006).

Therefore, the objective of this study was to create viable chick embryos without endogenous PGCs, taking advantage of the complement dependent cytotoxicity (CDC). We used antiSSEA1, Ig M monoclonal antibody, together with baby rabbit serum (BRS) as a source of complement to induce a selective ablation of the PGCs in stage X chicken embryos. These chicken embryos could be used as receptors for unique exogenous PGCs.

RESULTS

“In vitro” cytotoxicity of avian blastoderm cells

Competition tests of dispersed blastodermal cells with haemolytic system (HS) composed by sheep red blood cell (SRBCs) and haemolysin in gelatine-Veronal buffer with Ca^{2+} Mg^{2+} .

Haemolytic complement activity measures the complement classical pathway in serum. Fifty percentage of haemolytic complement activity (CH_{50} or K_d =dissociation constant) in competition curves, measures serum haemolysis capacity in SRBCs. CH_{50} is sensitive to any reduction of the classical pathway components. Therefore, haemolysis absorbance of SBRCs was evaluated (y-axis) with decreasing concentrations of baby rabbit serum (BRS) as a complement source (x-axis), without antiSSEA1 (yellow line) and with antiSSEA1 1/100

immunosurgery PGCs

(blue line) in presence of blastodermal cells. Saturation curve with dispersed blastodermal cells and antiSSEA1 1/100 revealed that, when blastodermal cells and antiSSEA1 were present, the saturation was reached and that the Kd (CH₅₀) was between 1/10 and 1/100 dilutions of BRS (Fig 1a). These dilutions were used for selective PGCs ablation studies. We performed next experiments focused on dilutions of 1/00 and 1/40 for antiSSEA1 and BRS, respectively.

Evaluation of cellular lysis with trypan blue after challenges with antiSSEA1 and BRS. In isolated blastoderms the cellular lysis was evident in zona pellucida, where PGCs are localized at this stage, while in control embryos none of the cells were stained (Fig 1b, A and B).

Figure 1. 1a Saturation curve.

Competition test with dispersed blastodermal cells and anti SSEA1 1/100. Haemolysis absorbance of sheep red blood cell (SRBC y-axis) with decreasing concentrations of baby rabbit serum (BRS) as a complement source (x-axis), without antiSSEA1 (yellow line) and with antiSSEA1 1/100 (blue line). When blastodermal cells and antiSSEA1 were present the saturation was reached and the CH₅₀ (Kd) was between 1/10 and 1/100 dilutions of BRS. Blastoderm cell suspensions from ten stage X embryos were used in each saturation curve. **1b. Deposition of antiSSEA1 and baby rabbit serum to the dorsal side of epiblast and evaluation of cellular lysis with trypan blue.** Chicken embryos stage X (A x4 and B x200), A) Control embryo treated with PBS and trypan blue exposed, none cell was stained by trypan blue (stereoscope Leica MZIII) B) Zona pellucida of one embryo challenged with antiSSEA1 and baby rabbit serum, there are blue cells stained (NIKON, Eclipse TE300, inverted microscope). C) Deposition of the treatment to the dorsal side of epiblast. D) 24 hours embryo, developmental stage referred in the manuscript as "early development".

immunosurgery PGCs

113 **Ex-ovo treatments applied to stage X embryos and incubated in surrogated egg shells**
 114 **following Perry's system II**

115 *Embryonic development and number of PGCs in embryos treated with deposition of*
 116 *antiSSEA1 and baby rabbit serum to the dorsal side of epiblast.* Two times of embryo
 117 development were evaluated, "early development" 24 hours after the application of the
 118 treatment (Fig 1b C and D) and "late development" 3-day. The evaluation of embryonic
 119 development revealed that the treatments and transfer manipulations did not affect neither
 120 embryo "early development" (67-100%) nor "late development" (56-90%) in any of the
 121 treated groups (AntiSSEA1 10/C+, 100/C+ and 1000/C+ groups) compared with control
 122 groups (AntiSSEA1-/C- and AntiSSEA1-/C+), Table 1. The mean survival days was 4.7, as
 123 expected in normal embryo development following Perry's system II (Fig 2a), with no
 124 significant differences between treatments. However, the number of PGCs detected was
 125 decreased in treated (4, 2.7 and 4 PGCs in AntiSSEA1 10/C+, 100/C+ and 1000/C+ groups,
 126 respectively) compared with control embryos (50 and 45 PGCs in AntiSSEA1-/C- and
 127 AntiSSEA1-/C+) (Fig 2b). A total of 2,400 tissue sections were immunostained and
 128 evaluated.

immunosurgery PGCs

Table 1. Embryos distribution of “early” and “late development” when the treatment was deposited to the dorsal side of epiblast at stage X. “Early development” 24 hours after the application of the treatment, the embryo continues to advance. “Late development” at day fourth embryos with heartbeat and vascular tree well formed.

Treatment	Nº embryos	Early development	Late development	Nº days
AntiSSEA1-/C- CONTROL	9	6	5	4.7
AntiSSEA1-/C+ CONTROL	8	8	7	5
AntiSSEA1 10/C+	12	8	7	4.5
AntiSSEA1 100/C+	11	11	9	4.8
AntiSSEA1 1000/C+	10	9	9	4.9
TOTAL	50	42 (67-100%)	37 (56-90%)	4.7

129

130

131 *Ex-ovo dose-response study with deposition of antiSSEA1 and baby rabbit serum to the dorsal*
132 *side of epiblast.* In all control embryos the PGCs counts were in the order of hundreds, while
133 the percentage of embryos with scarce or without PGCs were increasing with 1/10 and 1/100
134 concentration of antiSSEA1. The dose-response study evaluated “in toto” revealed that
135 antiSSEA1 100/C+ 1/40 was the most effective treatment destroying PGCs, because none of
136 PGCs were seen in any embryo receiving this treatment (Table 2 and Fig 2c).

immunosurgery PGCs

Figure 2. Treated embryos. The treatment was deposited to the dorsal side of epiblast. Days of survival (2a) and Number of PGCs (2b). PGCs were counted after a complete sectioning of embryos; a total of 2,400 tissue sections were evaluated. PGCs were immunochemically marked with antiSSEA1, biotinylated anti-mouse, followed by AP conjugated streptavidin and Fast Red. Three different experiments with at least 4 embryos per treatment group. 2c) Dose-response study in top-treated embryos, the PGCs were immunochemically marked with antiSSEA1 and antimouse alexa 488 "in toto". Y-axis percentage of embryos in each treatment group. X-axis: AntiSSEA1 (-, 1/10, 1/100 and 1/1000)/Baby rabbit serum or C (- or + at 1/40) designed as -/-, -/+, 10/+, 100/+ and 1000/+. Each group has at least three embryos.

137

Table 2. Results of dose-response study. The treatment was sequentially deposited to the dorsal side of epiblast. The majority of the embryos overpassed day 4 of development or 22 HH stage (Hamburger&Hamilton's classification). None embryo showed marked PGCs in the treated group antiSSEA1 100/C+.

Treatment AntiSSEA1/C	N° embryos	Developmental stage	Number of PGCs	% Embryos w/o PGCs
AntiSSEA1-/C-	3	26 HH 28 HH 22 HH	Hundreds Hundreds Hundreds	0
AntiSSEA1+10/C	3	29 HH 20 HH 23 HH	None None 44	33
AntiSSEA1+100/C	4	29 HH 29 HH 29 HH 10 HH	None None None None	100
AntiSSEA1+1000/C	6	29 HH 27 HH 29 HH 26 HH 29 HH 19 HH	Hundreds Hundreds None Hundreds None None	50
AntiSSEA1-/C-	5	29 HH 27 HH 24 HH 29 HH	Hundreds Hundreds 15 Hundreds Hundreds	0

138

immunosurgery PGCs

139 *Embryos treated with injections into the subgerminal space.* The evaluation of embryonic
140 survival revealed that the injected treatments and transfer manipulations did not affect neither
141 embryo “early development” (67-100%) nor “late development” (50-75%) in any of the
142 treated groups (AntiSSEA1 100/C+100, 100/C+1000 and /C+10000 groups) compared with
143 controls (AntiSSEA1-/C- and AntiSSEA1-/C+1000), Table 3. The mean survival for injected
144 embryos (4.4 days) was not different from top-dressed ones (4.7 days; Table 3 and Fig 3a).
145 The number of PGCs detected was decreased in treated (41, 28 and 45 PGCs in AntiSSEA1
146 100/C+100, 100/C+1000 and 1000/C+10000 groups, respectively) compared with control
147 embryos (82 and 100 PGCs in AntiSSEA1-/C- and AntiSSEA1-/C+1000, Fig 3b). The
148 maximum cytolytic activity was achieved with anti SSEA1 100/C+1000. The complement
149 alone did not show any cytolytic activity at 1/1000 dilution. Moreover, in a study of
150 complement cytotoxicity all 6 embryos injected with AntiSSEA1-/C10 developed and had a
151 high number of PGCs.

152 Unexpectedly, when antibody and complement were injected together in a single injection,
153 only half of the embryos reached “early development” and none “late development” (Table 3
154 and Fig 3a).

immunosurgery PGCs

Table 3. Embryo distribution of “early” and “late development” after subgerminal injections in chicken embryos at stage X. “Early development” 24 hours after the application of the treatment, the embryo continues to advance. “Late development” at day fourth embryos with heartbeat and vascular tree well formed.

Treatment AntiSSEA1/complement	N° embryos	Early development	Late development	N° days
AntiSSEA1-/C- CONTROL	12	9	6	4.7
AntiSSEA1+100/C+1000	10	8	8	4
AntiSSEA1+100/C+100	7	6	4	3.7
AntiSSEA1+100/C+1000	4	4	4	5
AntiSSEA1+100/C+10000	6	5	5	4.7
Cocktail	6	3	0	
TOTAL	43	35 (67-100%)	27 (50-75%)	4.4

155

Figure 3. Subgerminally injected stage X embryos. Days of embryo survival (3a) and Number of PGCs (3b). The PGCs were counted after sectioning of entire embryos, a total of 3,900 tissue sections were immunostained and evaluated. 3a) Days of embryo survival after sequential injections of antiSSEA1 (- or + 1/100) and C (-, 1/100, 1/1K and 1/10K). Joint injection of antiSSEA1 and baby rabbit serum (cocktail), none of embryos were developed. 3b) Number of PGCs, the maximum cytolytic activity was archived between antiSSEA1 +100-+/1K. The baby rabbit serum alone did not show any cytolytic action (-/1K).

156

immunosurgery PGCs

157

158 Immunocytochemistry and histological studies

159 *Immunohistochemistry in tissue sections.* In top-dressed and injected embryos, a total of 6,900

160 tissue sections were immunostained and the number of PGCs counted (Fig 4).

161

162 The data “number of PGCs” have been already presented above (Fig 2b and 3b).

163 *Immunohistochemistry “in toto”.* In order to stain PGCs the embryos needed a strong

164 permeabilization step (1% DMSO+0.1% triton X-100 in PBS overnight) and long periods of

165 antibodies incubations (antiSSEA1 and Ig G donkey antimouse alexa 488, with 48 and 24

166 hours at room temperature, respectively). In control embryos the presence of hundreds of

immunosurgery PGCs

PGCs can be visualized in Fig 5 A. In Fig 5B and 5C most of the PGCs are already in the gonads but some are in their way migrating from the aorta, only PGCs were marked.

In some embryos of the antiSSEA1-/C+ group the immunocytohistology showed hundreds of labelled cells in their gonads but the labeling was not as strong as in the antiSSEA1-/C- group (Fig 5D E). The confirmation of the PGCs presence was made with a histological Alcian Blue-PAS staining (Fig 5F). In contrast, none of the four treated embryos showed any PGCs (Fig 6 A', B', C' and D').

174

175

immunosurgery PGCs

176

177

178 DISCUSSION

179 Our results demonstrated that immune-mediated ablation is an effective method for
180 decimating the internal population of PGCs when preparing recipient chick embryos for germ
181 line chimera construction. Germ cell numbers can be substantially reduced while embryo
182 development is not affected. Treatment, dose and route had an impact on effectiveness and on
183 survivability.

184 “In vivo” top-dress application, directly on the germinal disc, is, by far, the best assayed. No
185 instrumentation is needed (stereomicroscope or micro injector) and it is the most gentle on the
186 embryo. The response, in terms of PGCs numbers in the gonads, was dose dependent. Almost
187 a complete ablation was achieved using antiSSEA1 and complement at 1/100 and 1/40

immunosurgery PGCs

188 dilutions, respectively. These doses are coincident with our results obtained in the “in vitro”
 189 competition studies with SBRCs. We must emphasize that the duration of embryonic
 190 development and the organic structures were normal. There was a concern that this form of
 191 administration could be insufficient, as the molecules of antiSSEA1 and complement must
 192 cross not only the vitelline membranes but also the blastoderm itself. Gerhart et al. were able
 193 to ablate two lineages of epiblast cells expressing skeletal muscle (MyoD) and neuronal
 194 (NeuroM) surface antigens (Gerhart et al. 2008; Gerhart et al. 2010). Supporting in part, our
 195 studies in using this route, since PGCs are concentrated on the hypoblast at stage X.

196 This was the reason why direct treatment injection on the subgerminal space, that is,
 197 immediately below the hypoblast, was also assayed. We expected this route would be more
 198 effective on PGCs but also more damaging on the embryo because of repeated puncture of the
 199 vitelline membrane. As anticipated, relative to top-dressing, sequential subgerminal
 200 application required less complement (antiSSEA1/100 plus C 1/1000), to yield an equally
 201 extensive PGCs ablation; survival of the embryos was, however, not impaired. There could be
 202 two reasons why less complement is needed when injected; first, the effective complement
 203 concentration around the target PGCs should be undoubtedly higher, as losses due to diffusion
 204 are minor; second, the antiSSEA1 labelling on the target cells is more extensive, since the
 205 injected antibody is not washed away after a short reaction time as when top-dressed.

206 In both strategies, the natural Ig and innate complement system present in BRS could be
 207 implicated (Gerencer et al. 1998). The most probable mechanism would be that once
 208 antiSSEA1 is bound to the outer Gal β (1-4), Fuc α (1-3)-GlcNAc β 1-R4 of PGCs, the rabbit
 209 innate complement system will consequently induce PGCs cytolysis by Complement Classical
 210 Pathway activation (C_{1q}). Gerhart’s results and the fact that in stage X embryos, neither
 211 complement enzymes nor IgM are present, support this mechanism. AntiSSEA1 has been

immunosurgery PGCs

212 frequently used to enrich PGCs isolates (Etches 1998 and Mozdziak 2006) although other
 213 antibodies have also been successful, as EMA-1, NC-1 and VASA. The later could be an
 214 optimum choice because of its specificity for germ line cells, as long as a good chicken
 215 antiVASA would be available.

216 We assayed a third administration strategy, joint injection of antiSSEA1 plus BRS into the
 217 subgerminal space, in case the double injection proved too detrimental to embryo viability.
 218 An unforeseen and remarkable disruption was observed on germinal disc development
 219 following injection of the antiSSEA1-BRS mixture. It suggests that a massive, untargeted
 220 cytolytic activity was developed that damaged several embryonic cell populations and
 221 structures. The only report on simultaneous use of antibody and serum (premixed before
 222 administration) “in vivo” is that of Takami et al. (2006) when treating a CNS lymphoma with
 223 rituximab, after previous treatment failures applying the antibody alone intraventricularly
 224 (Schulz et al. 2004). Generally, when the antibody-complement complex is used to direct a
 225 cytolysis over certain cell populations, the “modus operandi” is: the cells are first exposed to
 226 the antibody and, later on, the complement is applied to induce the lysis of only those cells
 227 previously targeted (Gerhart et al.2008, Gerhart et al. 2010, Chen and Melton 2007). Maybe
 228 other enzymes besides Cq1 of the complement system could be activated through the Lectin
 229 pathway. Several types of lectins present in serum have been studied, among them, mannose-
 230 binding lectins (bind to mannose) and ficolins (bind to GlcNAc or fucose). The latter need
 231 IgM to activate Lectin pathway (Endo et al. 2015). Humoral ficolins present in BRS could
 232 very well bind to IgM (antiSSEA1) when mixed and subsequently activate the complement
 233 enzymes (C₄ and C₂), which in turn, will destroy indiscriminately blastodermal cells.
 234 Supporting our hypotesis, Lei et al. (2015) have described a novel IgM–H-Ficolin
 235 complement pathway which ablates “in vitro” allogenic human cancer cells. Glycans covering
 236 blastodermal cells, as well as cancer cells, have GlcNAc and fucose (Endo et al. 2015 and Lei

immunosurgery PGCs

et al. 2015). In stage X chick embryos the glycocalyx of blastodermal cells and PGCs are richer in GlcNAc than in mannose (author unpublished observations). Taken together all we suggest a possible implication of IgM-ficolins complexes in this massive destruction. However, obviously the question of why antibody-complement together strongly increased cytolytic effects needs to be further investigated.

The use of monoclonal antibodies and complement is one of the most promising therapies in cancer. However, in long term treatments with specific antibodies, some tumours produce their own complement and others modulate the complement regulators resulting in the inhibition of the innate complement. As far as we know, premixing of exogenous complement and monoclonal antibody has not been reported as a strategy to boost antibody therapeutical effects. Our results are supported by the reported treatment of primary central nervous system lymphoma in humans using Rituximab (monoclonal antibody against primary lymphoma cells) and exogenous complement (Nishimura et al. 2003). Therefore, the mixture of antibody-complement previously to its local application could be very useful to treat large established tumours from which available antibodies exist and also to potentiate the antibody efficiency.

On the other hand, the lack of cytolytic response in our control, demonstrates that complement alone, even when directly injected into the subgerminal space at the highest concentration (C+1/10 dilution), is not cytotoxic for the developing stage X embryo: it failed to reduce the endogenous PGCs population and it did not affect embryo viability at all.

Therefore, two protocols successfully produced lysis of the primordial germ cells by specific cell labelling with antibody followed by heterologous serum with innate complement system present in BRS. Dress-on application is simpler and faster than subgerminal injection while equally effective, although larger quantities of reagents are needed. Both methods are capable

immunosurgery PGCs

261 of producing an almost complete ablation of the germline cells in chicken embryos with a
262 high efficiency without damaging other embryonic structures at stage X embryos.

263

264 **MATERIALS and METHODS**

265 **Egg source**

266 Freshly fertilized laid chicken eggs were obtained from Cobb SA (Alcalá de Henares, Madrid,
267 Spain). Housing and management of the laying hens (*Gallus gallus*, Linn) comply with
268 welfare and sanitary EU standards.

269 **“In vitro” cytolysis of avian blastoderm cells**

270 *Competition tests of dispersed blastodermal cells with haemolytic system (HS).* The optimal
271 dilution of the available complement systems was established in a complement assay with
272 baby rabbit serum (BRS) and haemolytic system (HS; SRBC and haemolysin in gelatine-
273 Veronal buffer containing Ca^{2+} and Mg^{2+} , SRBCs). All reactivities were generously supplied by
274 Margarita López Trascasa, Hospital La Paz, Madrid Spain. Indirect estimation of blastoderm
275 cytolysis was made using SRBCs, HS and blastoderm cells in competition assays. Maximum
276 haemolysis was induced by addition of distilled water to HS. The CH_{50} was established as the
277 range of those dilutions of BRS when haemolytic action was exhausted, and SRBCs started to
278 settle down in round-bottom ELISA plates.

279 A total of 32 blastoderms were isolated from embryonated eggs at oviposition and
280 disaggregated with repeated pipetting for three competitive studies. First, the blastoderm cell
281 suspensions of ten stage X embryos (300 μl approx 10^7 cells/ml) were incubated in assay
282 tubes with monoclonal antibody antiSSEA1 obtained as concentrate from the Developmental
283 Studies Hybridoma Bank (1/100 and 1/1000) during 45 minutes at 37°C in a water bath. Next,

immunosurgery PGCs

284 BRS (1/10; 1/100; 1/1000 and 1/10000) plus HS were added and, after incubation for an
 285 additional hour at 37°C in a water bath, the reaction cocktail was centrifuged 1000 g for 10
 286 minutes and the supernatant was transferred to a multi-well plate where absorbance at 405 nm
 287 was recorded. At the end of the second incubation, each reaction tube was evaluated for
 288 SRBC sedimentation: a reddish sediment in the tube reveals incomplete haemolysis since the
 289 complement in the reaction mix has been exhausted. Conversely, absence of SRBC sediment
 290 denotes excess complement activity in the mix. The degree of haemolysis was measured as
 291 the absorbance of the supernatants at 405nm. Saturation curves revealed that CH₅₀ was
 292 reached after adding BRS between a range of 1/10 -1/100 dilutions.

293 Next, a total of 26 entire blastoderms were isolated for the evaluation of cell viability
 294 described previously (Gerhart et al. 2008). In brief, each isolated embryo was placed in a well
 295 with cell culture medium M199 in four experiments following previously described culture
 296 conditions (Lopez-Diaz et al. 2016). Next, the blastoderms were challenged to antiSSEA1
 297 (1/100 and 1/1000) incubated during 45 minutes at 37°C and then to BRS (1/50). After
 298 incubation for an additional hour at 37°C, the evaluation of cell destruction was made adding
 299 4% trypan blue (4µl). Control blastoderms were incubated with only M199 or BRS+M199.

300 **Ex-ovo treatments applied to stage X embryos and incubated in surrogated egg shells** 301 **following Perry's system II**

302 *Deposition of antiSSEA1 and baby rabbit serum to the dorsal side of epiblast.* Embryonated
 303 chicken eggs at ovoposition (stage X) were cleaned with alcohol or with a solution of sodium
 304 hypochlorite for 30 or 60 minutes before use. The eggs content was poured on sterile Petri
 305 dishes to expose and manipulate the embryos following Gerhart's procedure (Gerhart et al.
 306 2008) with some variations. Briefly, the albumen covering the germinal disc was cleaned with
 307 sterile cellulose tissues until a well-marked hollowness appeared. Once the germinal discs

immunosurgery PGCs

308 were free from albumen, 100 µl of antiSSEA1 (1/10, 1/100 and 1/1000) were pipetted on top
 309 of the germinal disc and covered with a piece of parafilm. The treated embryos were
 310 incubated in an oven at 37°C saturated with moisture for 1 hour. The excess of unbound
 311 monoclonal antibody was washed away three times with PBS and BRS was immediately top-
 312 dressed on the blastoderm. Baby rabbit serum (diluted 1/40 in PBS + 0.1% skim milk) was
 313 used as a source of complement because it only has the innate complement system (C) and
 314 natural immunoglobulins, lacking immune IgG and IgM (Gerencer et al. 1998). The
 315 blastoderm was covered with parafilm and incubated for another hour in the same conditions.
 316 After washing the BRS, the contents of eggs were transferred to surrogate egg shells
 317 following Perry's system II (Perry, 1988). A total of 50 embryos were evaluated and
 318 histologically studied from three different experiments with at least 4 embryos per treatment
 319 group (antiSSEA1 -/C-; antiSSEA1 10/C+, antiSSEA1 100/C+, antiSSEA1 1000/C+ and
 320 antiSSEA1 -/C+).

321 *Treatment with two sequential injections into the subgerminal space.* Embryos were injected
 322 into the subgerminal space where PGCs are localized at stage X. First, a volume between 5-10
 323 µl of antiSSEA1 (1/100) was injected with micropipettes using a pneumatic fluid
 324 microinjector (Injectmatic, Geneva, CH). The treated embryos were incubated in an oven at
 325 37 °C saturated with moisture for 1 hour. Later, BSR was injected at different dilutions
 326 (1/100, 1/1000 and 1/10000). After the last injection the contents of eggs were transferred to
 327 surrogate egg shells. A total of 43 embryos were evaluated from three different experiments
 328 with at least 4 embryos per treatment group (antiSSEA1 -/C-, antiSSEA1 100/C100,
 329 antiSSEA1 100/C+1000, antiSSEA1 100/C+10000 and antiSSEA1 -/C+1000). In order to rule
 330 out a possible direct cytotoxic effect of BRS, a study was undertaken injecting subgerminally
 331 a maximum dose of complement 1/10 (antiSSEA1 -/C+10), including as well, a control group
 332 (antiSSEA1-/C-).

immunosurgery PGCs

333 *Treatment with a single injection into the subgerminal space.* Six embryos were injected into
 334 the subgerminal space as indicated above, except that antiSSEA1 and BRS were jointly
 335 applied in a single injection (antiSSEA1 10/C+10).

336 *Evaluation of embryo development.* Everyday “embryo development” was checked and
 337 recorded. Embryo development was recorded as “early development” on progress, if next day
 338 after the application of the treatment, germinal disc showed normal growth and no yolk
 339 leaking was seen. On third day “late development” was recorded as normal when the vessels
 340 were formed and the heart was beating. Embryos were incubated at least until 5-6 day in an
 341 egg incubator (Octagon) on system II (Perry 1988). Once the incubation was over or the
 342 embryo development stopped, the embryos were dissected, fixed and conserved in methanol
 343 70% until histological and immunohistological studies were undertaken.

344 **Immunocytochemistry and histological studies**

345 *Top-dressed and sequential injections into the subgerminal space embryos.* The presence of
 346 PGCs was assessed by an alkaline phosphatase (AP) immunocytochemical detection system
 347 using antiSSEA1 (DSHB; Iowa City, IA, U.S.A.). Briefly, embryos were fixed in Bouin’s
 348 solution overnight, embedded in parafine and entirely cut with microtome into tissue sections
 349 of 10 µm. A total of 6,300 tissue sections were analyzed (a mean of 100 tissue sections per
 350 embryo). To minimize nonspecific binding, the tissue slices were treated for 3 hours with 3%
 351 BSA and 0.1% triton X-100 in PBS before immunostaining. The optimal concentration of
 352 each antibody was selected based on the results of preliminary experiments (1/300 for
 353 antiSSEA1 and anti-mouse). Tissues were incubated for 24-48 hours with the primary
 354 antibody at 4°C and subsequently reacted for 24 hours each with biotinylated anti-mouse
 355 (Sigma B0529, for monoclonal first antibody) followed by AP conjugated streptavidin (Sigma
 356 E2636). Fast Red was used as substrate chromogen. To avoid interference by the potential

immunosurgery PGCs

357 endogenous activity of AP, the tissues were treated with 0.02 M levamisole or heat inactivated
358 at 70 °C for 30 minutes.

359 *Dose-response study.* In the dose-response study the number of PGCs was evaluated “in toto”
360 embryos by immunohistochemistry. Briefly, embryos were fixed in 4% paraformaldehyde in
361 PBS overnight at 4 °C, permeabilized using 1% DMSO and 0.1% triton X-100 in PBS
362 overnight and unspecific binding blocked at 4 °C overnight with 3% BSA and 0.1% triton X-
363 100 in PBS before immunostaining. The presence of PGCs was assessed by Ig G donkey
364 antimouse alexa 488 (24 hours at room temperature, Invitrogen) and antiSSEA1 as primary
365 antibody (48 hours of incubation). This immunohistochemistry allowed us a clear
366 identification of PGCs with absent fluorescent background. The nephros and gonads were
367 dissected and the number of PGCs twice counted under a stereoscope LEICA MZIII and an
368 inverted fluorescence microscope by two people (Nikon, Eclipse TE300; Tokyo, Japan, fitted
369 with a H910104A, TE-FM Epi-Fluorescence Lamp). The results were classified as: no cells =
370 none PGCs marked, countable cells = less than 100 marked PGCs and uncountable cells =
371 hundreds of PGCs were marked. In order to confirm that PGCs were marked, other
372 histological studies were made like PAS. In some embryos with weak fluorescece labelled
373 PGCs, specially all those treated only with complement, the gonads were stained with Alcian
374 Blue and PAS (Merk Germany 1.016460001) following the manufacturer’s instructions.
375 PGCs are Alcian Blue and PAS positive which gives a unique purple color at HH 27
376 developmental stage (5 days).

377 **Acknowledgements**

378 The authors acknowledge the valuable support of Dra Capitolina Díaz Martínez, President of
379 AMIT (Asociación de Mujeres Investigadoras y Tecnólogas). The valuable help of Soraya
380 Martínez-Alcocer and Diana González-Chamorro for histological processing is gratefully

immunosurgery PGCs

381 acknowledged. This study was partly supported by the grant AGL 2009E06345–MICINN
382 (Spain).

383 The monoclonal antibody antiSSEA1 developed by Solter and Knowles was obtained
384 from the Developmental Studies Hybridoma Bank developed under the auspices of the
385 NICHD and maintained by The University of Iowa, Department of Biology, Iowa City, IA
386 52242.

387

immunosurgery PGCs

388 **REFERENCES**

- 389 **1. Aige-Gil, V. and Simkiss, K.** 1991. Sterilisation of avian embryos with busulphan.
390 *Research in Veterinary Science.* 50: 139–144.
- 391 **2. Bresler, M., Behnam, J., Luke, G., and Simkiss, K.** 1994. Manipulations of germ-
392 cell populations in the gonad of the fowl. *Br. Poult. Sci.* 35, 241–247.
- 393 **3. Carsience, R., Clark, M., Verrinder Gibbins, A., Etches, R.** 1993. Germline
394 chimeric chickens from dispersed donor blastodermal cells and compromised recipient
395 embryos. *Development.* **117**, 669–675.
- 396 **4. Chen, A. E. and Melton, D.A.** 2007. Derivation of human embryonic stem cells by
397 immunosurgery. *J Vis Exp.* (10):574. doi: 10.3791/574. Epub 2007 Dec 13.
- 398 **5. Dubois, R.** 1969. Données nouvelles sur la localisation des cellules germinales
399 primordiales dans le germe non incubé de poulet. *C. R. Acad. Sci.* **269**, 205–208.
- 400 **6. Endo Y., Matsushita, M., Fujita, T.** 2015. New insights into the role of ficolins in
401 the lectin pathway of innate immunity. *Int Rev Cell Mol Biol.* **316**:49-110. doi:
402 10.1016/bs.ircmb.2015.01.003. Epub 2015 Feb 20.
- 403 **7. Etches R.** Methods for selecting germ-line competent cells in chicken embryos, and
404 the use of the cells in the production of chimeras. 1998. International Patent
405 Classification. C12N 5/06, A01K 67/027.
- 406 **8. Gerencer, M., Barrett, PN., Kistner, O., Mitterer, A., Dorner, F.** 1998. Natural
407 IgM antibodies in baby rabbit serum bind high-mannose glycans on HIV type 1
408 glycoprotein 120/160 and activate classic complement pathway. *AIDS Res Hum*
409 *Retroviruses.* **14**(7):599-605.
- 410 **9. Gerhart, J., Neely, C., Pfautz, J., George-Weinstein, M.** 2008. Tracking and
411 ablating subpopulations of epiblast cells in the chick embryo. *Biol Proced Online.* Sep
412 1;**10**:74-82. doi: 10.1251/bpo145.

immunosurgery PGCs

- 413 **10. Gerhart, J., Pfautz, J., Neely, C., Elder, J., DuPrey, K., , Menko, A.Sue., Knudsen**
414 **K. and George-Weinstein, M.** 2010. Noggin producing, MyoD-positive cells are
415 crucial for eye development. *Dev Biol.* 2009 December 1; 336(1): 30–41.
- 416 **11. Hemsworth, B. N., Jackson, H.** 1963. Effect of busulphan on the developing ovary in
417 the rat. *J Reprod Fert.* **6**: 229-233.
- 418 **12. Kalfayan , B., and Kidd, J. G.** 1953. Structural changes produced in Brown-Pearce
419 carcinoma cells by means of a specific antibody and complement. *J Exp Med.*1953
420 Jan;97(1):145-62.
- 421 **13. Kino, K. B., Pain, B., Leibo, M., Cochran, M., Clark, M. E., Etches, R. J.** (1997).
422 Production of chicken chimeras from injection of frozen-thawed blastodermal cells.
423 *Poult. Sci.* **76**:753–760.
- 424 **14. Kuwana, T. and Fujimoto, T.** 1984. Locomotion and scanning electron microscopic
425 observations of primordial germ cells from the embryonic chick blood *in vitro*. *Anat.*
426 *Rec.* **209**, 337-34.
- 427 **15. Lei, X., Liu, C., Azadzo, K., Li, C., Lu, F., Xiang, A., Sun, J., Guo, Y., Zhao, Q.,**
428 **Yan Z., Yang, J.** 2015. A novel IgM–H-Ficolin complement pathway to attack
429 allogenic cancer cells in vitro. *Scientific reports* | 5: 7824 | DOI: 10.1038/srep07824.
- 430 **16. Lia, C-H., Kagamib, H., Matsuib, K., Onob, T.** 2001. Restriction of proliferation of
431 primordial germ cells by the irradiation of Japanese quail embryos with soft X-rays.
432 *Comparative Biochemistry and Physiology. Part A* **130** 133_140.
- 433 **17. Lopez-Diaz, Mariacruz, Bujan-Varela, J., Cadorniga-Valiño, C.** 2016. Viable
434 pluripotent chick blastodermal cells can be maintained long term in an alkaline defined
435 medium. *In Vitro Cellular & Developmental Biology - Animal* (9989). DOI:
436 10.1007/s11626-015-9989-5.

immunosurgery PGCs

- 437 **18. Macor, P., and Tedesco, F.** 2007. Complement as effector system in cancer
438 immunotherapy. *Immunol Lett.* Jul 31; **111**(1):6-13. Epub 2007 May 29.
- 439 **19. Maeda, T., Clark, M. E., Etches, R. J.** 1998. Mortality, size of the gonads, and
440 ultrastructure of primordial germ cell in chick embryos treated with γ -irradiation or
441 injected with donor cells. *Poult. Sci.* **77**:905–907.
- 442 **20. Mozdziak, P. E., Wysocki, R., Angerman-Stewart, J., Pardue, S. L., and Petite,**
443 **J. N.** 2006. Production of Chick Germline Chimeras from Fluorescence-Activated
444 Cell-Sorted Gonocytes. *Poultry Science.* **85**:1764–1768.
- 445 **21. Muniesa, P. and Dominguez, L.** 1990. A morphological study of primordial germ
446 cells at pregastrular stages in the chick embryo. *Cell Differ Dev.* Aug; **31**(2):105-17.
- 447 **22. Naito M., Harumi T., Kuwana T.** 2015. Long-term culture of chicken primordial
448 germ cells isolated from embryonic blood and production of germline chimaeric
449 chickens. *Anim Reprod Sci.*Feb; **153**:50-61. doi: 10.1016/j.anireprosci.2014.12.003.
450 Epub 2014 Dec 24.
- 451 **23. Nakamura, Y., Usui, F., Miyahara, D., Mori, T., Ono, T., Kagami, H., Takeda,**
452 **K., Nirasawa, K., Tagami, T.** 2012. X-irradiation removes endogenous primordial
453 germ cells (PGCs) and increases germline transmission of donor PGCs in chimeric
454 chickens. *J Reprod Dev.* **58**(4):432-7. Epub 2012 Apr 13.
- 455 **24. Nishimura, R., Goto, Y., Maeba, H. et al.** 2003. Simultaneous supply of human
456 complement required for an effective treatment of CNS lymphomas with rituximab:
457 therapeutic experimental evidence. *Blood.* **102**: 4958a.
- 458 **25. Perry M. M.** 1988. A complete culture system for the chick embryo. *Nature.* 331, 70 -
459 72 (07 January 1988).

immunosurgery PGCs

- 460 **26. Petitte, J. N., Clark, M. E., Liu, G., Gibbins, A. M. V., Etches, R. J.** 1990.
461 Production of somatic and germline chimeras in the chicken by transfer of early
462 blastodermal cells. *Development*. **108**,185–189.
- 463 **27. Reynaud, G.** 1977. Action du Busulphan sure la lignee germinale de l’embryon de
464 poulet. *Bull. Soc. Zool. France* **102**, 41.
- 465 **28. Rogers, L. M., Veeramani, S., Weiner, G. J.** 2014. Complement in monoclonal
466 antibody therapy of cancer. *Immunol Res.* Aug;59(1-3):203-10. doi: 10.1007/s12026-
467 014-8542-z.
- 468 **29. Schulz, H., Pels, H., Schmidt-Wolf, I., Zeelen, U., Germing, U., Engert, A.** 2004.
469 Intraventricular treatment of relapsed central nervous system lymphoma with the anti-
470 CD20 antibody rituximab. *Haematologica*. **89**: 753–4.
- 471 **30. Song, Y., D’costa S., Pardue S. L., and Petitte J. N.** 2005. Production of Germline
472 Chimeric Chickens Following the Administration of a Busulfan Emulsion. *Molecular*
473 *Reproduction and Development*. **70**:438–444.
- 474 **31. Solter D. and Knowles B. B.** 1975. Immunosurgery of mouse blastocyst. *Proc Natl*
475 *Acad Sci U S A*. 1975 Dec; 72(12): 5099–5102.
- 476 **32. Speksnijder, G., and Ivarie, R.** 2000. A Modified Method of Shell Windowing for
477 Producing Somatic or Germline Chimeras in Fertilized Chicken Eggs. *Poultry Science*.
478 **79**:1430–1433.
- 479 **33. Stern, C.D.** 1991. The sub-embryonic fluid of the egg of the domestic fowl and its
480 relationship to the early development of the embryo. In: *Avian incubation*. (ed. S.G.
481 Tullett) London: Butterworths. pp. 81-90.
- 482 **34. Swift, H. M.** 1914. Origin and early history of the primordial germ-cells in the chick.
483 *Am J Anat.* U S A. **15**:486.

immunosurgery PGCs

- 484 **35. Takami, A., Hayashi, T., Kita, D., Nishimura, R., Asakura, H., Nakao, S.** 2006.
485 Treatment of primary central nervous system lymphoma with induction of
486 complement dependent cytotoxicity by intraventricular administration of autologous-
487 serum-supplemented rituximab. *Cancer Sci.* January 2006 vol. 97 no. 1 | 81.
- 488 **36. van de Lavoie, M.C., Diamond, J.H., Leighton, P.A., Mather-Love, C., Heyer,**
489 **B.S., Bradshaw, R., Kerchner, A., Hooi, L.T., Gessaro, T.M., Swanberg, S.E.,**
490 **Delany, M.E., Etches, R.J.** 2006. Germline transmission of genetically modified
491 primordial germ cells. *Nature*. Jun 8; **441**(7094):766-9.
- 492 **37. Whyte, J.; Glover, J.; Woodcock, M.; Brzezczynska, J.; Taylor, L.; Sherman,**
493 **A.; Kaiser, P.; McGrew, M.** 2015. FGF, Insulin, and SMAD Signaling Cooperate for
494 Avian Primordial Germ Cell Self-Renewal. In: *Stem Cell Reports*, 01.11.
- 495 **38. Wiemann, B., Starnes, C.O.** 1994. Coley's toxins, tumor necrosis factor and cancer
496 research: a historical perspective. *Pharmacol Ther.* **64**:529-564.
497

immunosurgery PGCs

498 **FIGURE LEGENDS**

499 **Figure 1. 1a Saturation curve. Competition test with dispersed blastodermal cells and**
500 **anti SSEA1 1/100.** Haemolysis absorbance of sheep red blood cell (SBRC y-axis) with
501 decreasing concentrations of baby rabbit serum (BRS) as a complement source (x-axis),
502 without antiSSEA1 (yellow line) and with antiSSEA1 1/100 (blue line). When blastodermal
503 cells and antiSSEA1 were present the saturation was reached and the CH50 (Kd) was between
504 1/10 and 1/100 dilutions of BRS. Blastoderm cell suspensions from ten stage X embryos were
505 used in each saturation curve. **1b. Deposition of antiSSEA1 and baby rabbit serum to the**
506 **dorsal side of epiblast and evaluation of cellular lysis with trypan blue.** Chicken embryos
507 stage X (Ax4 and B x200), A) Control embryo treated with PBS and trypan blue exposed,
508 none cell was stained by trypan blue (stereoscope Leica MZIII) B) Zona pellucida of one
509 embryo challenged with antiSSEA1 and baby rabbit serum, there are blue cells stained
510 (NIKON, Eclipse TE300, inverted microscope). C) Deposition of the treatment to the dorsal
511 side of epiblast. D) 24 hours embryo, developmental stage referred in the manuscript as "early
512 development".

513

514 **Figure 2. Treated embryos. The treatment was deposited to the dorsal side of epiblast.**
515 Days of survival (2a) and Number of PGCs (2b). PGCs were counted after a complete
516 sectioning of embryos, a total of 2,400 tissue sections were evaluated. PGCs were
517 immunochemically marked with antiSSEA1, biotinylated anti-mouse, followed by AP
518 conjugated streptavidin and Fast Red. Three different experiments with at least 4 embryos per
519 treatment group. 2c) Dose-response study in top-treated embryos, the PGCs were
520 immunochemically marked with antiSSEA1 and antimouse alexa 488 "in toto". Y-axis
521 percentage of embryos in each treatment group. X-axis: AntiSSEA1 (-, 1/10, 1/100 and

immunosurgery PGCs

522 1/100)/Baby rabbit serum or C (– or + at 1/40) designed as -/-, -/+, 10/+, 100/+ and 1000/+.

523 Each group has at least three embryos.

524

525 **Figure 3. Subgerminally injected stage X embryos.** Days of embryo survival (3a) and
526 Number of PGCs (3b). The PGCs were counted after sectioning of entire embryos, a total of
527 3,900 tissue sections were immunostained and evaluated. 3a) Days of embryo survival after
528 sequential injections of antiSSEA1 (- or + 1/100) and C (-, 1/100, 1/1K and 1/10K). Joint
529 injection of antiSSEA1 and baby rabbit serum (cocktail), none of embryos were developed.
530 3b) Number of PGCs, the maximum cytolytic activity was archived between antiSSEA1
531 +/100-+/1K. The baby rabbit serum alone did not show any cytolytic action (-/1K).

532

533 **Figure 4. Histology of embryos treated with antiSSEA1 and baby rabbit serum. Top-**
534 **dressed stage X embryos.** Sections of gonads from control and treated embryos (5-days). A
535 and B Control embryo PBS treated, only PGCs are immunochemically marked with
536 antiSSEA1, biotinylated anti-mouse, followed by AP conjugated streptavidin and Fast Red
537 (AX200 and BX400). C and D treated embryo showing one red cell colony (orange arrow),
538 very few PGCs were counted in all sections. A total of 2,400 tissue sections were
539 immunostained and analyzed. Haematoxilin counterstaining (C X100 and D X200).

540

541 **Figure 5. In vivo dose-response study in stage X embryos top-treated.** The presence of
542 PGCs was assessed by immunohistochemistry “in toto”. A control embryo only PGCs were
543 stained. B and C, most of the PGCs are already in the gonads but some are in their way
544 migrating from the aorta (C). D and D’ Nephros and gonads from an embryo treated with
545 BRS (anti-SSEA1 -/C+). Leica MZIII. Embryos needed a permeabilization step (1%
546 DMSO+0.1% triton X-100 in PBS overnight) and long periods of antibodies incubations

immunosurgery PGCs

547 (antiSSEA1 and Ig G donkey antimouse alexa 488, with 48 and 24 hours at room temperature,
548 respectively). LG=left gonad, RG=right gonad and A=aorta. E) Histology of D embryo's
549 gonads (grey circles), PGCs in the gonads are purple (PAS and Alcian blue positives).
550 Embryo was Alcian Blue and PAS stained "in toto" and then sectioned (X100).

551

552 **Figure 6. Treated embryos from "in vivo" dose-response study in stage X embryos top-**
553 **treated.** Embryo development did not progress beyond 6 days (HH 29). A B and C treated
554 embryos with absence of PGCs. A B C and A', B', C' visible light and fluorescence.
555 AntiSSEA1 immunocytochemistry was made "in toto" with antimouse alexa 488. Embryos
556 evaluated under fluorescence stereoscope Leica MZIII. G=gonad N=nephros.

557

558 **Table 1. Embryos distribution of "early" and "late development" when the treatment**
559 **was deposited to the dorsal side of epiblast at stage X.** "Early development" 24 hours after
560 the application of the treatment, the embryo continues to advance. "Late development" at day
561 fourth embryos with heartbeat and vascular tree well formed.

562

563 **Table 2. Results of dose-response study.** The treatment was sequentially deposited to the
564 dorsal side of epiblast. The majority of the embryos overpassed day 4 of development or 22
565 HH stage (Hamburger&Hamilton's classification). None embryo showed marked PGCs in the
566 treated group antiSSEA1 100/C+.

567

568 **Table 3. Embryo distribution of "early" and "late development" after subgerminal**
569 **injections in chicken embryos at stage X.** "Early development" 24 hours after the
570 application of the treatment, the embryo continues to advance. "Late development" at day
571 fourth embryos with heartbeat and vascular tree well formed.

immunosurgery PGCs

572

573

574 **Competing interests**

575 The authors declare no competing or financial interests.

576 **Role of the founding source**

577 This study was supported by the grant AGL 2009E06345–MICINN (Spain).

578